Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Dose Generic Plerixafor for Stem Cell Mobilization
NCT06892119Phase 1Completed
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lymphoma and multiple myeloma (MM) comparing Generic plerixafor with Placebo (2 arms). Primary endpoint: Post-RD plerixafor increase in CD34+/μL pre-count, final CD34+ cell yield and harvest at 1 year. Started Dec 2019; status: completed.
02
Drugs
plerixafor
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06892119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892119.